Subtype
Malignant Intestinal Neoplasm
CI-CAN-00001137Explore in graph →
1,666 active trials21 approved drugs383 evidence items
- NCIt
- C4572
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001137Explore in graph →
Clinical trials
7,771 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (772)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02173990 | Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).(PULSAR) | terminated | Phase 2 | 40 | Centre Oscar LambretOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02851004 | Special Combination of BBI608 and Pembrolizumab | terminated | Phase 1 / Phase 2 | 55 | Takayuki YoshinoOTHER | 1 | Sep 5, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT03311750 | Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer(A-REPEAT) | terminated | Phase 2 | 23 | Hellenic Cooperative Oncology GroupOTHER | 2 | Jun 7, 2021 | clinicaltrials |
| NCT02448810 | Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer | terminated | Phase 2 | 115 | Baxalta now part of ShireINDUSTRY | 1 | May 25, 2021 | clinicaltrials |
| NCT03158610 | Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer | terminated | Phase 2 / Phase 3 | 20 | Ruijin HospitalOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT02117466 | Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer(IMPACT-CRC) | terminated | Phase 1 / Phase 2 | 85 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 14, 2021 | clinicaltrials |
| NCT00005944 | Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer | terminated | Phase 2 | — | UNICANCEROTHER | 2 | Feb 17, 2021 | clinicaltrials |
| NCT03149679 | The p53 Colorectal Cancer Trial | terminated | Phase 2 | 12 | Haukeland University HospitalOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT03170115 | Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer(ICAR) | terminated | Phase 2 | 25 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Dec 17, 2020 | clinicaltrials |
| NCT00986440 | Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy | terminated | Phase 2 | 84 | Daiichi SankyoINDUSTRY | 9 | Nov 5, 2020 | clinicaltrials |
| NCT02010567 | Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer | terminated | Phase 1 / Phase 2 | 32 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT00671645 | Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy | terminated | Phase 2 | 8 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03549338 | Sym004 Versus Futuximab or Modotuximab in Patients With mCRC | terminated | Phase 2 | 2 | Symphogen A/SINDUSTRY | 4 | Sep 28, 2020 | clinicaltrials |
| NCT01367275 | Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
| NCT02652702 | Study Comparing Circular Stapler-assisted Colostomy vs Hand-stitching Colostomy of Colorectal Cancer Patients(STAPLER) | terminated | Phase 2 | 60 | Zhejiang UniversityOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT00602329 | MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer | terminated | Phase 2 | 5 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | terminated | Phase 2 | 12 | Mayo ClinicOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT00353457 | Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma | terminated | Phase 2 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Apr 9, 2020 | clinicaltrials |
| NCT02141295 | A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer(McCAVE) | terminated | Phase 2 | 197 | Hoffmann-La RocheINDUSTRY | 7 | Mar 25, 2020 | clinicaltrials |
| NCT01504477 | Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer | terminated | Phase 1 / Phase 2 | 6 | Georgetown UniversityOTHER | 1 | Mar 16, 2020 | clinicaltrials |
| NCT01057017 | First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras | terminated | Phase 2 | 5 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01669720 | Adjuvant Aflibercept for Metastatic Colorectal Cancer(C261) | terminated | Phase 2 | 10 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01671488 | A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer(276) | terminated | Phase 1 / Phase 2 | 11 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT00955240 | Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer | terminated | Phase 2 | 16 | UNICANCEROTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02425683 | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX | terminated | Phase 2 | 24 | US Oncology ResearchINDUSTRY | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01532804 | 2nd-line Treatment of Metastatic Colorectal Cancer(BEVATOMOX) | terminated | Phase 2 | 83 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT00580073 | Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum | terminated | Phase 2 | 6 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01902823 | Effect of Cancer Nurse Navigators on Patient Outcomes | terminated | Phase 2 / Phase 3 | 16 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02318901 | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer(PembroMab) | terminated | Phase 1 / Phase 2 | 16 | Western Regional Medical CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT00397878 | AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03204201 | Validation of ICG to Identify the Urethra During Rectal Surgery | terminated | Phase 1 / Phase 2 | 5 | Oxford University Hospitals NHS TrustOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03204994 | Fluorescence Targeted Pelvic Lymph Node Mapping | terminated | Phase 1 / Phase 2 | 1 | Oxford University Hospitals NHS TrustOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03431311 | T Cell Receptor Based Therapy of Metastatic Colorectal Cancer(TCR-CRC-001) | terminated | Phase 1 / Phase 2 | 1 | Oslo University HospitalOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT03645876 | SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer | terminated | Phase 2 | 12 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT03070574 | Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome(MesaCAPP) | terminated | Phase 2 | 8 | Christoph GascheOTHER | 6 | Apr 18, 2019 | clinicaltrials |
| NCT01479465 | Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma | terminated | Phase 2 | 266 | Gilead SciencesINDUSTRY | 7 | Apr 17, 2019 | clinicaltrials |
| NCT02568046 | Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients | terminated | Phase 1 / Phase 2 | 10 | Symphogen A/SINDUSTRY | 2 | Mar 26, 2019 | clinicaltrials |
| NCT02402036 | A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer | terminated | Phase 2 | 10 | Georgetown UniversityOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT00611858 | Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer | terminated | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01925274 | A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer | terminated | Phase 2 | 19 | PfizerINDUSTRY | 4 | Jan 8, 2019 | clinicaltrials |
| NCT01523639 | A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis(G-LUCAS) | terminated | Phase 2 | 8 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 1 | Dec 19, 2018 | clinicaltrials |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT02216149 | Effects of S-1 and Capecitabine on Coronary Artery Blood Flow(FluoHeart) | terminated | Phase 2 | 20 | Heikki JoensuuOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT02508077 | FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT02654639 | Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer(ALEXANDRIA) | terminated | Phase 2 | 4 | Georgetown UniversityOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT00845039 | A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab(FC-4) | terminated | Phase 2 | 4 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Oct 20, 2021source: clinicaltrials